Switch theme
Sign up to access all valuation multiples
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
2012
71
LTM Revenue $56.7M
LTM EBITDA -$19.5M
$120M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
908 Devices has a last 12-month revenue (LTM) of $56.7M and a last 12-month EBITDA of -$19.5M.
In the most recent fiscal year, 908 Devices achieved revenue of $59.6M and an EBITDA of -$67.8M.
908 Devices expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 908 Devices valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $56.7M | XXX | $59.6M | XXX | XXX | XXX |
| Gross Profit | $34.9M | XXX | $29.9M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | -$19.5M | XXX | -$67.8M | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -114% | XXX | XXX | XXX |
| EBIT | -$36.1M | XXX | -$49.3M | XXX | XXX | XXX |
| EBIT Margin | -64% | XXX | -83% | XXX | XXX | XXX |
| Net Profit | -$42.6M | XXX | -$72.2M | XXX | XXX | XXX |
| Net Margin | -75% | XXX | -121% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, 908 Devices's stock price is $7.
908 Devices has current market cap of $240M, and EV of $120M.
See 908 Devices trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $120M | $240M | XXX | XXX | XXX | XXX | $-1.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, 908 Devices has market cap of $240M and EV of $120M.
908 Devices's trades at 2.0x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate 908 Devices's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
908 Devices has a P/E ratio of -5.6x.
See valuation multiples for 908 Devices and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV (current) | $120M | XXX | $120M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -3.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.6x | XXX | -3.3x | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial908 Devices's last 12 month revenue growth is 7%
908 Devices's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.1M for the same period.
908 Devices's rule of 40 is -60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
908 Devices's rule of X is -16% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 908 Devices and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -114% | XXX | XXX | XXX |
| EBITDA Growth | -61% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -60% | XXX | -106% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -16% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 133% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
908 Devices acquired XXX companies to date.
Last acquisition by 908 Devices was XXXXXXXX, XXXXX XXXXX XXXXXX . 908 Devices acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 908 Devices founded? | 908 Devices was founded in 2012. |
| Where is 908 Devices headquartered? | 908 Devices is headquartered in United States of America. |
| How many employees does 908 Devices have? | As of today, 908 Devices has 71 employees. |
| Who is the CEO of 908 Devices? | 908 Devices's CEO is Dr. Kevin J. Knopp, PhD. |
| Is 908 Devices publicy listed? | Yes, 908 Devices is a public company listed on NAS. |
| What is the stock symbol of 908 Devices? | 908 Devices trades under MASS ticker. |
| When did 908 Devices go public? | 908 Devices went public in 2020. |
| Who are competitors of 908 Devices? | Similar companies to 908 Devices include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of 908 Devices? | 908 Devices's current market cap is $240M |
| What is the current revenue of 908 Devices? | 908 Devices's last 12 months revenue is $56.7M. |
| What is the current revenue growth of 908 Devices? | 908 Devices revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of 908 Devices? | Current revenue multiple of 908 Devices is 2.1x. |
| Is 908 Devices profitable? | Yes, 908 Devices is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 908 Devices? | 908 Devices's last 12 months EBITDA is -$19.5M. |
| What is 908 Devices's EBITDA margin? | 908 Devices's last 12 months EBITDA margin is -34%. |
| What is the current EV/EBITDA multiple of 908 Devices? | Current EBITDA multiple of 908 Devices is -6.1x. |
| What is the current FCF of 908 Devices? | 908 Devices's last 12 months FCF is -$22.8M. |
| What is 908 Devices's FCF margin? | 908 Devices's last 12 months FCF margin is -40%. |
| What is the current EV/FCF multiple of 908 Devices? | Current FCF multiple of 908 Devices is -5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
